Cardiac Resynchronisation Therapy in Patients with NYHA Class I–II

  • C. Linde
Chapter

Conclusions

Cardiac resynchronisation therapy improves HF symptoms and reduces HF-related hospitalisations and total mortality in patients with moderate to severe HF and ventricular dyssynchrony. In smaller studies, CRT has also been shown be beneficial in patients with less symptomatic HF. The effects of CRT on HF outcomes is therefore currently being studied in patients with NYHA II heart failure or ALVD.

Keywords

Chronic Heart Failure Cardiac Resynchronisation Therapy Heart Failure Patient NYHA Class Biventricular Pace 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anonymous (2003) Heart disease and stroke statistics — 2004 update. American Heart Association. In: http://www.americanheart.org/downloadable/heart/1079736729696HDSStats2004UpdateREV3-19-04.pdfGoogle Scholar
  2. 2.
    Mosterd A, Hoes AW, de Bruyne MC et al (1999) Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 20:447–455PubMedCrossRefGoogle Scholar
  3. 3.
    McDonagh TA, Robb SD, Murdoch DR et al (1998) Biochemical detection of left-ventricular systolic dysfunction. Lancet 351:9–13PubMedCrossRefGoogle Scholar
  4. 4.
    Konstam MA, Kronenberg MW, Rousseau MF et al (1993) Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 88:2277–2283PubMedGoogle Scholar
  5. 5.
    The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685–691CrossRefGoogle Scholar
  6. 6.
    Wang TJ, Evans JC, Benjamin EJ et al (2003) Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108:977–982PubMedCrossRefGoogle Scholar
  7. 7.
    Levy D, Kenchaiah S, Larson MG et al (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347:1397–1402PubMedCrossRefGoogle Scholar
  8. 8.
    Venkateshawar K, Gottipaty K, Krelis P (1999) The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic congestive heart failure. J Am Coll Cardiol 33:145A (abs)Google Scholar
  9. 9.
    Baldasseroni S, Opasich C, Gorini M et al (2002) Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 143:398–405PubMedCrossRefGoogle Scholar
  10. 10.
    Silvet H, Amit J, Padmanabhan S (1999) Increased QRS-duration reduces survival in patients with left ventricular dysfunction: results form a cohort of 2263 patients. J Am Coll Cardiol 33:145A (abs)Google Scholar
  11. 11.
    McMurray J, McDonagh T, Morrison CE et al (1993) Trends in hospitalization for heart failure in Scotland 1980–1990. Eur Heart J 14:1158–1162PubMedGoogle Scholar
  12. 12.
    Berry C, Murdoch DR, McMurray JJ (2001) Economics of chronic heart failure. Eur J Heart Fail 3:283–291PubMedCrossRefGoogle Scholar
  13. 13.
    Ryden-Bergsten T, Andersson F (1999) The health care costs of heart failure in Sweden. J Intern Med 246:275–284PubMedCrossRefGoogle Scholar
  14. 14.
    Cazeau S, Leclercq C, Lavergne T et al (2001) Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344:873–880PubMedCrossRefGoogle Scholar
  15. 15.
    Abraham WT, Fisher WG, Smith AL et al (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845–1853PubMedCrossRefGoogle Scholar
  16. 16.
    Stellbrink C, Breithardt OA, Franke A et al (2001) Impact of cardiac resynchronization therapy using hemodynamically optimised pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. J Am Coll Cardiol 38:1957–1965PubMedCrossRefGoogle Scholar
  17. 17.
    Linde C, Leclercq C, Rex S et al (2002) Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 40:111–118PubMedCrossRefGoogle Scholar
  18. 18.
    St John Sutton MG, Plappert T, Abraham WT et al (2003) Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107:1985–1990PubMedCrossRefGoogle Scholar
  19. 19.
    Abraham WT, Young JB, Smith AL et al (2004) Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. Circulation 110:2864–2868PubMedCrossRefGoogle Scholar
  20. 20.
    Young JB, Abraham WT, Smith AL et al (2003) Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289:2685–2694PubMedCrossRefGoogle Scholar
  21. 21.
    Bristow MR, Saxon LA, Boehmer J et al (2004) Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150PubMedCrossRefGoogle Scholar
  22. 22.
    Cleland JGF, Daubert JC, Erdmann E et al (2001) on behalf of the CARE-HF Steering Committee and Investigators. The CARE-HF study (Cardiac Resynchronisation in Heart Failure study) rationale, design and end-points. Eur Heart Failure 3:481–489CrossRefGoogle Scholar
  23. 23.
    Higgins SL, Hummel JD, Niazi IK et al (2003) Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 42:1454–1459.PubMedCrossRefGoogle Scholar
  24. 24.
    Packer M (2001) Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 7:176–182PubMedCrossRefGoogle Scholar
  25. 25.
    Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling — concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35:569–582PubMedCrossRefGoogle Scholar
  26. 26.
    Bristow MR, Gilbert EM, Abraham WT et al (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94:2807–2816PubMedGoogle Scholar
  27. 27.
    Kawai K, Takaoka H, Hata K et al (1999) Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 84:671–676PubMedCrossRefGoogle Scholar
  28. 28.
    The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II)(1999): a randomised trial. Lancet 353:9–13CrossRefGoogle Scholar
  29. 29.
    Packer M, Coats AJ, Fowler MB et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658PubMedCrossRefGoogle Scholar
  30. 30.
    Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL (1999) Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007Google Scholar
  31. 31.
    Lau CP, Yu CM, Chau E et al (2000) Reversal of left ventricular remodeling by synchronous biventricular pacing in heart failure. Pacing Clin Electrophysiol 23:1722–1725.PubMedGoogle Scholar
  32. 32.
    Hunt SA, Baker DW, Chin MH et al (2002) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant 21:189–203PubMedCrossRefGoogle Scholar
  33. 33.
    Linde C, Gold M, Abraham WT, Daubert JC (2005) for the REVERSE study group. Rationale and design of a randomised controlled clinical study to assess if cardiac resynchronisation therapy can slow disease progression in mild to moderate heart failure — The Resynchronisation reVerses Remodelling in aSymptomatic left vEntricular dysfunction (REVERSE) study. Am Heart J (in press)Google Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • C. Linde
    • 1
  1. 1.Department of CardiologyKarolinska University HospitalStockholmSweden

Personalised recommendations